<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618629</url>
  </required_header>
  <id_info>
    <org_study_id>Z215-03</org_study_id>
    <nct_id>NCT02618629</nct_id>
  </id_info>
  <brief_title>Mass Balance and Metabolism Study of 14C-Z-215</brief_title>
  <official_title>A Phase I Mass Balance and Metabolism Study of 14C-Z-215 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeria Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeria Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this Phase I study is to determine the absorption, metabolism, and excretion of
      14C-Z-215 in healthy male subjects following a single oral administration at a
      therapeutically relevant dose level (20 mg).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity concentration in plasma, red blood cells and whole blood</measure>
    <time_frame>Predose,15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Z-215 in plasma</measure>
    <time_frame>Predose,15 and 30 minutes, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 14, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity in urine</measure>
    <time_frame>Predose, 0 to 6, 6 to 12, 12 to 24, 24 to 36, 36 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, 144 to 168, 168 to 192, 192 to 216, 216 to 240 hours postdose, Day 15 (336 hours postdose), Day 19 (432 hours postdose), Day 23 (528 hours postdose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance recovery of total radioactivity in faecal</measure>
    <time_frame>Predose, 0 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, 144 to 168, 168 to 192, 192 to 216, 216 to 240 hours postdose, Day 15 (336 hours postdose), Day 19 (432 hours postdose), Day 23 (528 hours postdose)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>14C-Z-215</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-Z-215</intervention_name>
    <description>Single oral dose of 20mg Z-215 and 14C-Z-215 solution</description>
    <arm_group_label>14C-Z-215</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any race/ethnic origin

          -  Subjects will have a body mass index (BMI) between 18.5 and 30.0 kg/m2

          -  Subjects will have a body weight between 50 and 110 kg

          -  Subjects will have given their written informed consent to participate in the study,
             and to abide by the study restrictions.

        Exclusion Criteria:

          -  Subjects who have a significant history of drug allergy, as determined by the
             Investigator.

          -  Subjects who have serum hepatitis or are carriers of the hepatitis B surface antigen
             (HBsAg) or the hepatitis C antibody.

          -  Subjects who have a positive result for the test for human immunodeficiency virus
             (HIV) antibodies.

          -  Subjects who are exposed to radiation as a result of their occupation.

          -  Subjects who, in the opinion of the Investigator, should not participate in this
             study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>UK</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

